Literature DB >> 11110623

Update on peripheral arterial vasodilation, ascites and hepatorenal syndrome in cirrhosis.

M Knotek1, B Rogachev, R W Schrier.   

Abstract

In cirrhosis of the liver, according to the peripheral arterial vasodilation hypothesis, relative underfilling of the arterial tree triggers a neurohumoral response (activation of renin-angiotensin-aldosterone system, sympathetic nervous system, nonosmotic release of vasopressin) aimed at restoring circulatory integrity by promoting renal sodium and water retention. Evidence has accumulated for a major role of increased vascular production of nitric oxide as the primary cause of arterial vasodilation in cirrhosis. Ascites is a common complication in cirrhosis. Treatment of ascites consists of a low salt diet with diuretics, and paracentesis together with plasma volume expanders in diuretic-resistant patients. Progression of cirrhosis may result in hepatorenal syndrome, a state of functional renal failure that carries an ominous prognosis. Orthotopic liver transplantation has remained the only curative treatment for patients with advanced liver disease; other modalities such as transjugular intrahepatic portosystemic shunt or vasopressin analogues may serve as a bridge to transplantation. Another complication of decompensated cirrhosis is spontaneous bacterial peritonitis, the incidence of which can be reduced by primary or secondary antibiotic prophylaxis by using orally active antibiotics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11110623     DOI: 10.1155/2000/340128

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  4 in total

Review 1.  Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists.

Authors:  Ahmed A Magan; Atif A Khalil; Mohamed H Ahmed
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

2.  Vasopressin deficiency and vasodilatory state in end-stage liver disease.

Authors:  Gebhard Wagener; Galina Kovalevskaya; Moury Minhaz; Fallon Mattis; Jean C Emond; Donald W Landry
Journal:  J Cardiothorac Vasc Anesth       Date:  2010-12-03       Impact factor: 2.628

3.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.

Authors:  Arun J Sanyal; Thomas Boyer; Guadalupe Garcia-Tsao; Frederick Regenstein; Lorenzo Rossaro; Beate Appenrodt; Andres Blei; Veit Gülberg; Samuel Sigal; Peter Teuber
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

4.  The safety and effectiveness of 2-liter polyethylene glycol plus ascorbic acid in patients with liver cirrhosis: A retrospective observational study.

Authors:  Jae Min Lee; Jae Hyung Lee; Eun Sun Kim; Jung Min Lee; In Kyung Yoo; Seung Han Kim; Hyuk Soon Choi; Bora Keum; Yeon Seok Seo; Yoon Tae Jeen; Hong Sik Lee; Hoon Jai Chun; Soon Ho Um; Chang Duck Kim
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.